MUMBAI, India, Nov. 5, 2025 /CNW/ -- Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the Second Quarter (Q2) and Half Year (H1) ended 30(th) September 2025.
Consolidated Financial Highlights (in Crores or as stated) Particulars Q2FY26 Q2FY25 YoY Growth H1FY26 H1FY25 YoY Growth Revenue from Operations 2,044 2,242 (9) % 3,977 4,193 (5) % CDMO 1,044 1,324 (21) % 2,041 2,381 (14) % CHG 644 643 0 % 1,281 1,274 1 % ICH 319 277 15 % 621 541 15 % EBITDA 224 403 (44) % 389 627 (38) % EBITDA Margin 11 % 18 % 10 % 15 % PAT (99) 23 NM (181) (66) NM
Key Highlights for Q2 and H1 FY26
-- Revenue from Operations for the quarter and half-year FY26 stood at 2,044
crores and 3,977 crores respectively. The YoY growth was impacted due to
inventory destocking by the customer in one large CDMO order.
-- EBITDA margin for the quarter and half-year FY26 were 11% and 10%
respectively. Despite lower revenues in H1FY26, its impact on EBITDA was
partly offset by our efforts towards cost optimization and operational
excellence.
-- Net-Debt at the end of H1FY26 reduced by 228 crores (vs. FY25) to 3,971
crores supported by tight control over working capital and capex
investments, maintaining our net debt to EBITDA ratio below 3x.
-- Sustainability-- Released our 4th Annual Sustainability Report for the
FY25, under the theme 'Innovating Responsibly. Growing Sustainably',
which has also been assured by DNV Business Assurance India Pvt Ltd. The
report outlines measurable progress and strengthened commitments under
our four strategic pillars.
Nandini Piramal, Chairperson, Piramal Pharma Limited said, "YoY growth in the CDMO Businesswas primarily impacted by inventory destocking in one large on-patent commercial product. Inconsistent recovery in US biopharma funding along with uncertainties on global trade policies led to adverse impact on order inflows and customer decision making during H1FY26. However, in the months of September and October 2025, we have seen a significant pick up in biopharma funding, which if sustains, should lend impetus to increased RFPs and orders going forward. Also, we are seeing strong customer interest for onshore offerings which bodes well for the investments we have made in our overseas sites. In our CHG business we further strengthened our leadership position in the US Sevoflurane market, while simultaneously working to obtain regulatory approvals for ex-US markets from our India plant. Our consumer business delivered healthy mid-teen growth, seamlessly collaborating with various stakeholders for smooth transition to new GST rates changes."
Key Business Highlights for Q2/H1 FY2026 Contract Development and Manufacturing Organization $(CDMO)$ : - YoY growth during Q2 and H1 FY26 was primarily impacted by inventory destockingby the customer in one large CDMO order for on-patent commercial product. - Inconsistent recovery in US biopharma funding along with uncertainties on global trade policies led to adverse impact on order inflow and decision making by customers in H1FY26. Although, seeing early signs of improvement with funding uptick in the months of September and October 2025. - Efforts towards cost optimization and operational excellence helped partially offset impact on EBITDA. - Recently increasing RFPs/RFIs- especially for our onshore manufacturing facilities and differentiated capabilities like ADC, Sterile fill-finish, and on-patent commercial manufacturing, where we have made significant investments in capabilities and capacities. - Good progress in the existing development pipeline -- Entered into a multi-million-dollar joint investment at Sellersville site (US), with NewAmsterdam Pharma for commercial manufacturing capacity for FDC of Obicetrapib and Ezetimibe to meet commercial demand. - Best-in-Class Quality Track Record -- Successfully closed 19 regulatory inspections, including 1 USFDA inspection with zero observations in H1FY26. Continue to maintain our 'Zero OAI' status. Complex Hospital Generics (CHG): - Inhalation Anesthesia (IA) - o Continue to further strengthen our leadership position in the mature US Sevoflurane market with value market share of 45% in Mar'25 - up from 44% in MAT Mar'24. (Source:- IQVIA) o To drive growth, we are working on obtaining regulatory approvals for Sevoflurane in the ex-US markets from our Digwal plant in India. - Intrathecal Therapy -- Sales during the quarter was impacted due to temporary supply challenges. Expect supplies to normalize in H2FY26. Maintained our #1 Rank in intrathecal Baclofen in the US with 75% value market share. (Source:- IQVIA) - Injectable Anesthesia and Pain Management -- Initiatives to resolve supply constraints starting to yield results. - Differentiated and Specialty Products - Continue to invest in 505(b)(2)'s, complex generics, differentiated generics, and branded products through in-licensing deals or co-development projects to enable long term growth. Piramal Consumer Healthcare $(PCH)$: - Power Brands continue to post strong growth of 20% YoY during Q2FY26, contributing to 51% of total PCH sales. Growth was primarily driven by Little's, Lacto Calamine, CIR, and i-range. - New Product Launches - Added 26 new products and SKUs in H1FY26. - Investments in Media and Promotions - 12% of PCH sales in H1FY26. - E-commerce sales grew at over 40% YoY in Q2 and H1FY26, contributing about 24% to PCH sales. More than 40% of e-commerce sales coming from quick commerce. Consolidated Profit and Loss Statement (in Crores or as stated) Particulars Quarterly Half Yearly Q2FY26 Q2FY25 YoY Q1FY26 QoQ H1FY26 H1FY25 YoY Change Change Change Revenue from Operations 2,044 2,242 (9) % 1,934 6 % 3,977 4,193 (5) % Other Income 66 61 7 % 58 12 % 124 81 54 % Total Income 2,109 2,303 (8) % 1,992 6 % 4,101 4,274 (4) % Material Cost 703 796 (12) % 694 1 % 1,397 1,471 (5) % Employee Expenses 611 560 9 % 619 (1) % 1,230 1,139 8 % Other Expenses 571 544 5 % 514 11 % 1,085 1,037 5 % EBITDA 224 403 (44) % 165 36 % 389 627 (38) % Interest Expenses 82 108 (23) % 86 (4) % 169 215 (21) % Depreciation 203 192 6 % 197 3 % 400 377 6 % Share of Net Profit of Associates 15 17 (14) % 19 (20) % 33 40 (16) % Profit Before Tax (46) 120 NM (100) NM (146) 75 NM Tax 53 98 (46) % 3 1,879 % 56 141 (61) % Net Profit after Tax (99) 23 NM (102) NM (202) (66) NM Exceptional item(1) - - NM 21 NM 21 - NM Net Profit after Tax after Exceptional Item (99) 23 NM (82) NM (181) (66) NM 1.Exceptional items include, one time insolvency proceeds received from a claim filed against a third-party supplier of our complex hospital generics business, with the NCLT in November 2023 Consolidated Balance Sheet (in Cr. or as stated) Key Balance Sheet Items As at 30-Sep-25 31-Mar-25 Total Equity 8,073 8,125 Net Debt 3,971 4,199 Total 12,045 12,324 Net Fixed Assets 9,394 9,110 Tangible Assets 4,655 4,534 Intangible Assets including goodwill 3,651 3,599 CWIP (including IAUD(2) ) 1,088 977 Net Working Capital 2,201 2,798 Other Assets(3) 450 416 Total Assets 12,045 12,324 2. IAUD -- Intangible Assets Under Development; 3. Other Assets include Investments and Deferred Tax Assets (Net)
Q2 and H1 FY26 Earnings Conference Call
Piramal Pharma Limited will be hosting a conference call for investors / analysts on 06(th) November 2025 from 9:30 AM to 10:15 AM(IST)to discuss its Q2 and H1 FY26 Results.
The dial-in details for the call are as under:
Event Location & Time Telephone Number
Conference call on India -- 09:30 AM IST +91 22 6280 1461 / +91
06(th) November, 2025 22 7115 8320 (Primary
Number)
1 800 120 1221 (Toll
free number)
USA -- 11:00 AM (Eastern Toll free number
Time -- New York) 18667462133
UK -- 04:00 AM (London Toll free number
Time) 08081011573
Singapore -- 12:00 PM Toll free number
(Singapore Time) 8001012045
Hong Kong -- 12:00 PM Toll free number
(Hong Kong Time) 800964448
Express Join with Diamond Please use this link for prior registration to Pass$(TM)$ reduce wait time at the time of joining the call --Click here
About Piramal Pharma Limited:
Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17(1) global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions $(PPS)$, an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and Piramal Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments.
1. Includes one facility via PPL's minority investment in Yapan Bio.
For more information, visit: Piramal Pharma | LinkedIn
Logo - https://mma.prnewswire.com/media/1855206/Piramal_Pharma_Limited_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/piramal-pharma-limited-announces-results-for-q2-and-h1-fy26-302605982.html
SOURCE Piramal Pharma Limited
/CONTACT:
Copyright CNW Group 2025
(END) Dow Jones Newswires
November 05, 2025 12:58 ET (17:58 GMT)